FeesSafety
Pluang+

City Therapeutics to present RNAi drug data for thromboembolic diseases and anemia at ASH 2026

Market News
04 Nov 2026, 16:01 WIB
GlobeNewsWire
View Source
Bullish
City Therapeutics to present RNAi drug data for thromboembolic diseases and anemia at ASH 2026

City Therapeutics announced it will present data on its RNA interference (RNAi) drug candidates CITY-FXI and CITY-TFR2 at the 68th ASH Annual Meeting in December 2026. CITY-FXI, targeting Factor XI for thromboembolic diseases, will be featured in an oral presentation with Phase 1 clinical trial results from healthy volunteers and patients with specific genetic mutations. CITY-TFR2, aimed at treating anemia of chronic disease, will be presented in a poster session showcasing preclinical data. These presentations highlight City Therapeutics' progress in developing innovative RNAi therapies for serious blood and anemia conditions.

City Therapeutics' RNAi candidates CITY-FXI and CITY-TFR2 provide context for health sector activity on Pluang as of Nov 04, 2026 20:41 WIB. Of 150 priced health stocks, 127 rose and 19 fell. Among notable movers, HRTX gained 5.37% at USD 0.30 with a buy-heavy order split of 66%, contrasting with CVS which dropped 4.93% at USD 86.90 despite 91% buy orders. ZBH also rose 5.09% to USD 102.00, holding a longer typical Pluang hold time of 90 days compared to HRTX's 38 days.

More News

Kelly Technology + Motion Recruitment named Leader by Everest Group for US IT staffing and consulting excellence

Kelly Technology + Motion Recruitment named Leader by Everest Group for US IT staffing and consulting excellence

Kelly Technology + Motion Recruitment, a division of Kelly Services, has been recognized as a Leader on Everest Group's 2026 U.S. IT Contingent Talent and Strategic Solutions PEAK Matrix® for its expertise in specialized IT staffing, consulting, and ...

Market News
Bullish
16 minutes ago
Sutro Biopharma to present at multiple investor conferences in November and December 2026

Sutro Biopharma to present at multiple investor conferences in November and December 2026

Sutro Biopharma, a clinical-stage oncology company specializing in antibody drug conjugates (ADCs), announced its participation in several investor conferences in November and December 2026, including events hosted by Stifel, Truist Securities, UBS, ...

Market News
Neutral
1 hour ago
etoro acquires Argentine fintech LB Finanzas to expand in Latin America

etoro acquires Argentine fintech LB Finanzas to expand in Latin America

etoro has agreed to acquire LB Finanzas, a leading Argentine all-in-one financial app, to strengthen its presence in Latin America's fast-growing fintech market. LB Finanzas offers integrated investing and payment solutions, catering to Argentine ret...

Company Fundamentals
Bullish
1 hour ago
JD.com to release Q3 2026 financial results on Nov 17 with a management call scheduled.

JD.com to release Q3 2026 financial results on Nov 17 with a management call scheduled.

JD.com announced it will publish its unaudited financial results for the third quarter of 2026 on November 17, before the U.S. market opens. The company's management will hold a conference call the same day to discuss the results, providing investors...

Company Fundamentals
Neutral
4 hours ago
KE Holdings to release Q3 2026 financial results on Nov 16 with a live earnings call.

KE Holdings to release Q3 2026 financial results on Nov 16 with a live earnings call.

KE Holdings Inc., a major online and offline housing platform in China, will announce its unaudited financial results for the third quarter of 2026 on November 16 before the U.S. market opens. The company will host an earnings conference call at 7:00...

Company Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App